Pharmaceutical

Verve Therapeutics gets grant for gene editing compositions to lower ldl cholesterol levels

Discover how Verve Therapeutics' new patent for gene editing targeting the PCSK9 gene could revolutionize LDL cholesterol treatment and combat cardiovascular disease.

Aug 23, 2024 - 04:00
Discover how Verve Therapeutics' new patent for gene editing targeting the PCSK9 gene could revolutionize LDL cholesterol treatment and combat cardiovascular disease.
Read the original article

Tags:

Previous Article

Novartis and Versant launch Borealis Biosciences with $150m

Next Article

Frequency Therapeutics gets grant for oligonucleotide compositions for treating ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA rejects Aldeyra’s dry eye drug, asks for more clinical data

FDA rejects Aldeyra’s dry eye drug, asks for more clini...

Nov 28, 2023

In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease

In historic decision, FDA approves a CRISPR-based medic...

Dec 9, 2023

OSE Immunotherapeutics’ Tedopi gains US patent for cancer treatment

OSE Immunotherapeutics’ Tedopi gains US patent for canc...

Jul 5, 2023